Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Immix Biopharma, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

LOS ANGELES, CA, OCT. 06, 2025 (GLOBE NEWSWIRE) -- IMMIX BIOPHARMA, INC. (IMMIXBIO, COMPANY, WE OR US OR IMMX), THE GLOBAL LEADER IN RELAPSED/REFRACTORY AL AMYLOIDOSIS, TODAY ANNOUNCED THAT IT WILL PRESENT A NXC-201 ABSTRACT AT THE UPCOMING AMERICAN SOCIETY OF HEMATOLOGY (ASH) 67TH ANNUAL MEETING AND EXPOSITION TO BE HELD DECEMBER 6-9, 2025, IN ORLANDO, FLORIDA.

IMMIX BIOPHARMA TO PRESENT ABSTRACT AT THE UPCOMING ASH 2025 ANNUAL MEETING

LOS ANGELES, CA, OCT. 01, 2025 (GLOBE NEWSWIRE) -- IMMIX BIOPHARMA, INC. (IMMIXBIO, COMPANY, WE OR US OR IMMX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING CELL THERAPIES FOR AL AMYLOIDOSIS AND OTHER SERIOUS DISEASES, TODAY ANNOUNCED THAT IT WILL PRESENT AND HOST INSTITUTIONAL INVESTOR MEETINGS AT THE 37TH ANNUAL PIPER SANDLER HEALTHCARE CONFERENCE BEING HELD ON DECEMBER 2-4, 2025 AT THE LOTTE NEW YORK PALACE HOTEL IN NEW YORK, NY.

IMMIX BIOPHARMA TO PRESENT AT THE 37TH ANNUAL PIPER SANDLER HEALTHCARE CONFERENCE

 ON TRACK FOR FIRST FDA BIOLOGICS LICENSE APPLICATION (BLA) APPROVED CELL THERAPY IN ORPHAN INDICATION RELAPSED/REFRACTORY AL AMYLOIDOSIS 

IMMIX BIOPHARMA ANNOUNCES 50% ENROLLMENT MILESTONE SURPASSED IN ITS ONGOING RELAPSED/REFRACTORY AL AMYLOIDOSIS CLINICAL TRIAL, NEXICART-2

 DR. CHANG LED XOLAIR FROM INVENTION THROUGH FDA APPROVAL AND COMMERCIALIZATION, EXCEEDING $5 BILLION IN SALES SO FAR 

NANCY T. CHANG, PROVEN BIOTECHNOLOGY LEADER, JOINS IMMIX BIOPHARMA BOARD OF DIRECTORS

LOS ANGELES, CA, SEPT. 08, 2025 (GLOBE NEWSWIRE) -- IMMIX BIOPHARMA, INC. (IMMIX, COMPANY, WE OR US OR IMMX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING CELL THERAPIES FOR AL AMYLOIDOSIS AND OTHER SERIOUS DISEASES, TODAY ANNOUNCED THAT IT HAS RECEIVED A STRATEGIC INVESTMENT FROM GOOSE CAPITAL AND FORMER TANOX, INC. CEO DR. NANCY T. CHANG, GOOSE FOUNDING MEMBER.

IMMIX BIOPHARMA ANNOUNCES STRATEGIC INVESTMENT BY HOUSTON BASED GOOSE CAPITAL, LED BY FOUNDING MEMBER DR. NANCY T. CHANG

LOS ANGELES, CA, AUG. 25, 2025 (GLOBE NEWSWIRE) -- IMMIX BIOPHARMA, INC. (IMMIXBIO, COMPANY, WE OR US OR IMMX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING CELL THERAPIES FOR AL AMYLOIDOSIS AND OTHER SERIOUS DISEASES, TODAY ANNOUNCED THAT IT WILL PRESENT AND HOST INSTITUTIONAL INVESTOR MEETINGS AT THE STIFEL 2025 HEALTHCARE CONFERENCE BEING HELD ON NOVEMBER 11-13, 2025 AT THE LOTTE NEW YORK PALACE HOTEL IN NEW YORK, NY.

IMMIX BIOPHARMA TO PRESENT AT THE STIFEL 2025 HEALTHCARE CONFERENCE

 DOSING ONGOING AND PLANNED IN A HANDFUL OF OTHER SERIOUS DISEASES (OSD)   COMPANY PLANS TO PARTNER-OUT OTHER SERIOUS DISEASE PROGRAMS   ON TRACK FOR FIRST BIOLOGICS LICENSE APPLICATION (BLA) APPROVED CELL THERAPY IN LEAD INDICATION RELAPSED/REFRACTORY AL AMYLOIDOSIS  LOS ANGELES, CA, AUG. 06, 2025 (GLOBE NEWSWIRE) -- IMMIX BIOPHARMA, INC. (IMMIXBIO, COMPANY, WE OR US OR IMMX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING CELL THERAPIES FOR AL AMYLOIDOSIS AND OTHER SERIOUS DISEASES, TODAY ANNOUNCED IMPORTANT UPDATES ABOUT ITS PLAN TO ADDRESS OTHER SERIOUS DISEASES WITH ITS STERICALLY-OPTIMIZED BCMA-TARGETED CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPY NXC-201 WITH A DIGITAL FILTER THAT FILTERS OUT NON-SPECIFIC ACTIVATION. THE COMPANY PLANS TO RELEASE FORTHCOMING CLINICAL DATA AT UPCOMING SCIENTIFIC FORUMS.

IMMIX BIOPHARMA ANNOUNCES OTHER SERIOUS DISEASES STRATEGY

 ABSENCE OF NEUROTOXICITY OF ANY GRADE IN LOW-VOLUME DISEASE TO-DATE   ON TRACK FOR FIRST BIOLOGICS LICENSE APPLICATION (BLA) APPROVED CELL THERAPY IN ORPHAN INDICATION RELAPSED/REFRACTORY AL AMYLOIDOSIS   POTENTIAL FUTURE INDICATION EXPANSION PLANNED  LOS ANGELES, JULY 11, 2025 (GLOBE NEWSWIRE) -- IMMIX BIOPHARMA, INC. (IMMIXBIO, COMPANY, WE OR US OR IMMX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING CELL THERAPIES FOR AL AMYLOIDOSIS AND OTHER SERIOUS DISEASES, TODAY ANNOUNCED A CLASS-LEADING SAFETY PROFILE FOR STERICALLY-OPTIMIZED CAR-T NXC-201, INCLUDING ABSENCE OF NEUROTOXICITY OF ANY GRADE IN LOW-VOLUME DISEASE TO-DATE, LAYING A FOUNDATION FOR POTENTIAL FUTURE INDICATION EXPANSION. WE ARE SINGULARLY FOCUSED ON COMPLETING NEXICART-2 FOR BLA SUBMISSION, WHERE WE ARE ACCELERATING PROGRESS.

IMMIX BIOPHARMA ANNOUNCES CLASS-LEADING SAFETY PROFILE, ALLOWING POTENTIAL FUTURE INDICATION EXPANSION

 NATIONAL FOOTPRINT OF NEXICART-2 TRIAL SITES EXPANDED   ON TRACK FOR FIRST BIOLOGICS LICENSE APPLICATION (BLA) APPROVED CELL THERAPY IN UNADDRESSED ORPHAN INDICATION   NEXICART-2 INTERIM RESULTS WERE PRESENTED AT ASCO 2025  LOS ANGELES, CA, JULY 07, 2025 (GLOBE NEWSWIRE) -- IMMIX BIOPHARMA, INC. (IMMIXBIO, COMPANY, WE OR US OR IMMX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING CELL THERAPIES FOR AL AMYLOIDOSIS AND OTHER SERIOUS DISEASES, TODAY ANNOUNCED ACCELERATED U.S. NEXICART-2 CLINICAL TRIAL PROGRESS IN RELAPSED/REFRACTORY AL AMYLOIDOSIS. NEXICART-2 NOW INCLUDES 18 CLINICAL TRIAL SITES IN ITS NATIONAL FOOTPRINT.

IMMIX BIOPHARMA ANNOUNCES ACCELERATED NEXICART-2 CLINICAL TRIAL PROGRESS IN RELAPSED/REFRACTORY AL AMYLOIDOSIS

 SELECTED TO ATTEND IN-PERSON EVENT ON JUNE 5 LED BY FDA COMMISSIONER MARTY A. MAKARY, M.D.

Immix Biopharma, Inc.

IMMX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Immix Biopharma, Inc.

IMMX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

IMMX